wamj-transwhitelogo.png
  • Interview

    • Cover Story
    • Entrepreneur
  • Reports

    • Biopharma
    • Special Report
  • News & Events

    • Conference
    • Latest News
  • Publication

  • About Us

    • About WAMJ
    • Editorial Board
    • Editorial Letter
    • Sponsorship
  • More

    Use tab to navigate through the menu items.
    • All
    • Cover Story
    • Entrepreneur
    • Biopharmaceutical reports
    • Special Reports
    • Letter
    • Conference
    • Latest Issue
    • biopharma r1
    • biopharma r2
    • biopharma r3
    • special r1
    • cover r1
    • letter r1
    • latest r1
    • con r1
    • cover r2
    Search
    Anlysis of Bio - Pharma in East Asia - Trends Report

    Anlysis of Bio - Pharma in East Asia - Trends Report

    Biopharmaceutical Report III Issue6_April 2015 Featured Story of Korean Pharma: Hanwha confirms abandoning bid for Dow Chemical basic...
    Astellas/Medivation's Xtandi has questionable potential to displace bicalutamide

    Astellas/Medivation's Xtandi has questionable potential to displace bicalutamide

    Biopharmaceutical Report II Issue6_April 2015 Astellas (TYO:4503)/Medivation's (NASDAQ:MDVN) Phase II TERRAIN study topline data on...
    Spark's LCA2 gene therapy is likely to have greater benefit for younger patients

    Spark's LCA2 gene therapy is likely to have greater benefit for younger patients

    Biopharmaceutical Report I Issue6_April 2015 Spark Therapeutics' (NASDAQ:ONCE) subretinal gene therapy injection of SPK-RPE65, is likely...
    Biosimilar Reference
Products Expected to Grow

    Biosimilar Reference Products Expected to Grow

    Biopharmaceutical Report II Issue5_February 2015 • Logistic complications create high demand for the expertise of comparator suppliers •...
    Diabetic Neuropathy Patient Stratification, Chances Boosted

    Diabetic Neuropathy Patient Stratification, Chances Boosted

    Biopharmaceutical Report I Issue5_February 2015 • Phase II signals encouraging for positive Phase III translation • Capsaicin as...
    J&J may suffer over AbbVie,Amgen in renewed biologic USpayer contracts as Celltrion’sbiosimilar loom

    J&J may suffer over AbbVie,Amgen in renewed biologic USpayer contracts as Celltrion’sbiosimilar loom

    Biopharmaceutical Report II Issue4_November 2014 • Remsima use may be forced ahead of Remicade, but not Humira or Enbrel • ...
    Array/Novartis’ binimetinib expected to best chemotherapy in Phase III trial despite protocol change

    Array/Novartis’ binimetinib expected to best chemotherapy in Phase III trial despite protocol change

    Biopharmaceutical Report I Issue4_November 2015 • Enrollment criteria expanded mid-trial to reflect shifting treatment landscape • ...
    The Unrealized Potential of
Stem Cell Therapy

    The Unrealized Potential of Stem Cell Therapy

    Biopharmaceutical Report III Issue3_September 2014 Over the last decade or so, I have observed a tempering of what was once a large and...
    *Novartis’ LCZ696 for CHFdraws approval optimism aftermeeting difficult Phase IIIendpoints

    *Novartis’ LCZ696 for CHFdraws approval optimism aftermeeting difficult Phase IIIendpoints

    Biopharmaceutical Report II Issue3_September 2014 • Superiority to standard therapy bodes well for approvals • Regulators may require...
    *Celgene's Revlimid has experts optimistic about potential in Phase III non-del (5q) MDS trial in tr

    *Celgene's Revlimid has experts optimistic about potential in Phase III non-del (5q) MDS trial in tr

    Biopharmaceutical Report I Issue3_September 2014 • Historical responses meaningful, but approvability based on transfusion changes...
    1/2
    • Grey Facebook Icon
    • Grey Twitter Icon
    • Grey LinkedIn Icon

    Subscribe to Our Journal

    Thanks for submitting!

    Email: wgroup@wmedical.org
    Tel: 201-402-1400